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Sporadic
Cancer syndromeMalignant mesothelioma (MM) is a uniformly fatal tumour caused predominantly by exposure to asbestos. It is
not known why some exposed individuals get mesothelioma and others do not. There is some epidemiological
evidence of host susceptibility. BAP1 gene somatic mutations and allelic loss are common in mesothelioma and
recently a BAP1 cancer syndrome was described in which affected individuals and families had an increased
risk of cancer ofmultiple types, includingMM. To determine if BAP1mutations could underlie any of the sporadic
mesothelioma cases in our cohort of patients, we performed targeted deep sequencing of the BAP1 exome on the
IonTorrent Proton sequencer in 115 unrelatedMMcases. No exonic germline BAP1mutations of known function-
al signiﬁcance were observed, further supporting the notion that sporadic germline BAP1mutations are not rel-
evant to the genetic susceptibility of MM.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malignant mesothelioma (MM) is an aggressive, incurable tumour
of serosal surfaces. Along with the principal causative agent asbestos,
there is evidence of genetic involvement in MM oncogenesis, with a re-
ported two-fold increased rate of MM in individuals with a ﬁrst-degree
relative with MM, after adjustment for asbestos exposure (de Klerk
et al., 2013). Recently, germline mutations in BRCA1-associated protein
1 (BAP1)were reported inMMpatients (Testa et al., 2011). Themajority
of MM cases with germline BAP1 mutations arise in individuals or
families with a strong history of malignancy, including uveal melanoma
(Testa et al., 2011; Carbone et al., 2012; Ribeiro et al., 2013), though
the original study also reported that 7.7% (2/26) of sporadic MM
cases carried BAP1 germline mutations (Testa et al., 2011). Of noteRCA1 associated protein-1;NF2,
rphism; DNA, deoxyribonucleic
ey).
. This is an open access article underthese two cases were reported to have no known asbestos exposure.
However, subsequent studies of nearly 200 sporadic European MM
cases have not identiﬁed any relevant germline BAP1mutations (Betti
et al., 2015; Rusch et al., 2015). The identiﬁcation of genetic susceptibil-
ity markers for MM, that are independent of asbestos exposure, could
impact on the screening of asbestos-exposed individuals and has the
potential to affect the medico-legal responsibilities of governments
and the asbestos manufacturing/production industry. Because this
is an important issue we conducted the current study to determine
the prevalence of germline BAP1 mutations in our cohort of patients
with MM.
2. Methods
Germline DNA was analysed from 115 unrelated predominantly
European-Australian MM patients randomly selected from a previously
described cohort (Cadby et al., 2013). A 3584 bp region of BAP1 includ-
ing all exons and 3′ and 5′ untranslated regions were sequenced using
Ion Ampliseq (Life Technologies, Victoria, Australia) protocols and re-
agents on the Ion Torrent Proton sequencer using an Ion PIv2 chip
(Life Technologies) as described by the manufacturer. Sequencedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mapping Alignment Program. Germline DNAmutations were identiﬁed
using the Torrent Suite variant caller plugin with high stringency
germline parameters and annotated using Ion Reporter 4.2 (Life
Technologies). All variants were assessed visually using Integrative
Genomics Viewer (Thorvaldsdottir et al., 2013). In addition, germline
variants were independently identiﬁed using the Genome Analysis
Toolkit (McKenna et al., 2010). Single nucleotide polymorphisms
(SNPs) were annotated against the current dbSNP database (dbSNP
build 142), SIFT (Kumar et al., 2009) and PolyPhen-2 (Adzhubei et al.,
2010) databases using ANNOVAR (Wang et al., 2010). Novel SNPs and
small insertions and deletions (indels) were considered signiﬁcant
when located in coding regions and predicted to be deleterious by either
SIFT or PolyPhen-2. This studywas approved by the Ethics Committee of
Sir Charles Gairdner Hospital.3. Results
There were 115 unrelated MM cases in this study; 12 cases were
female and N90% were known to have been exposed to asbestos.
Sixty cases had tumours with epithelial histology, 14 biphasic, 6
sarcomatoid and 35 were of unspeciﬁed histologies or had a diagnosis
made on immunocytological grounds. The overallmean age at diagnosis
was 68 years (range 42–94) and median survival for the group was 15
(95%CI 11–19) months. BAP1 exons were sequenced to a median
depth of 1736x (interquartile range 566–1213). No germline BAP1
mutations of any known functional signiﬁcance were observed in
the 115 MM cases. A total of 8 known SNPs were identiﬁed within
the BAP1 locus, with minor allele frequencies (MAF) ranging from
0.1 to 3.4% (Table 1). The three exonic SNPs were synonymous and
of no known functional signiﬁcance. A single base insertion was
identiﬁed in an intronic region between exons 1 and 2 of 7 samples
and was of unknown signiﬁcance. The frequency of SNPs within BAP1
(0.089%) was in accordance with the expected rate (0.1%) reported by
the International HapMap Consortium (International HapMap, 2003).
In addition, three SNPs were identiﬁed in the downstream region
of the BAP1 gene. All detected SNPs were in Hardy–Weinberg
equilibrium. Assuming a prevalence of germline BAP1 mutations
of 7.7% in MM patients as previously described (Testa et al., 2011),
the Poisson distribution probability that there were no mutations in
the 115 cases was p = 0.0001, or p = 10−10 if all three studies on
sporadic MM were combined (Testa et al., 2011; Betti et al., 2015;
Rusch et al., 2015). Conversely, the upper 95% conﬁdence limit
for zero mutations out of 115 cases was 2.6% or 1.0% with all 3
studies combined.Table 1
SNPs identiﬁed in an unselected general population sampling of 115 individuals within BAP1.
Chrm 3 location Location in BAP1 Mutation Heterozygo
52443786 Intronic
(between exon 1 and 2)
Insertion 7
52440827 Intronic
(between exon 8 and 9)
1
52440418 Intronic
(between exon 8 and 9)
2
52439240 Exon 11 Synonymous 2
52439216 Exon 11 Synonymous 1
52437748 Exon 13 Synonymous 1
52436917 Intronic
(between exon 14 and 15)
2
52435860 UTR3 12
a VAF = variant allele frequency in the context of the sample population.
b MAF =minor allele frequency as reported by 1000 Genomes.
c ND = not described.4. Conclusion
Using targeted resequencing, no BAP1 germline mutations of
known functional signiﬁcance were identiﬁed in 115 MM cases.
Variation in the sample population was consistent with the expected
rate for an outbred population. These data provide support for two re-
cent studies showing no known functionally signiﬁcant BAP1 germline
mutations in 78 MM patients (Rusch et al., 2015) and 103 MM cases
(Betti et al., 2015).
It is of note that the twoMM cases reported by Testa and colleagues
to harbour germline BAP1mutations also had uveal and cutaneousmel-
anoma with no known asbestos exposure. It is possible that these two
MMcaseswere associatedwith the recently described BAP1 cancer syn-
drome (Testa et al., 2011; Carbone et al., 2012; Ascoli et al., 2014). The
phenotype of this syndrome often includes uveal and cutaneous mela-
noma, and has been associated with other cancers such as melanocytic
tumours (Wiesner et al., 2011) and renal cell carcinomas (Popova
et al., 2013). The absence of uveal melanomas in our large population
of MM patients further supports the notion that this familial BAP1 syn-
drome is a rarity.
In our studywe examined the prevalence of BAP1mutations in unre-
latedMM cases. In some instances DNAwas available from one or more
ﬁrst degree relatives who also developed MM. Such families are part of
our asbestos surveillance programme (de Klerk et al., 2013) and have
varying degrees of asbestos exposure. There was no indication of famil-
ial BAP1 mutations in eight families examined (data not shown),
although other as yet unknown genetic susceptibility factors may be
present.
Whether genetic factorsmay play a role inMM is unclear.Whether a
germline mutation can predispose an individual to develop MM via a
traditional Knudson-like two-hit carcinogenesis model (Knudson,
1971) or whether it can affect the susceptibility of the individual to
the carcinogenic properties of asbestos remain to be determined. From
genetically engineered mouse models of mesothelioma it is apparent
that loss of the neuroﬁbromatosis type 2 (NF2) gene and/or Ink4a/Arf
and p53 is sufﬁcient to induce MM in the absence of asbestos, or to
accelerate MM development following asbestos exposure, but these
genetic losses are not MM-speciﬁc and a range of different tumours
can develop in these mice (Jongsma et al., 2008). In mice expressing
the oncogene SV40 T antigen in the mesothelial cell compartment,
MM is only observed following asbestos exposure (Robinson et al.,
2006). Recently, Bap1+/− knockout mice were found to have increased
susceptibility to asbestos induced MM compared to wild type litter
mates (Xu et al., 2014). In conclusion, germline BAP1 mutations are
not a major predisposing factor to asbestos-induced MM in Australian
population-based studies.tes (no.) Homozygotes (no.) VAFa Reference SNP MAFb
0 0.030 NDc
0 0.004 ND
0 0.009 rs139414598 0.005
0 0.009 rs28997577 0.005
0 0.004 rs71651686 0.001
0 0.004 rs34736117 0.016
0 0.009 rs146661777 ND
0 0.052 rs123598 0.034
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